Last reviewed · How we verify
Fucidin® cream
Fucidin® cream is a Steroid antibiotic Small molecule drug developed by LEO Pharma. It is currently FDA-approved for Bacterial skin infections caused by susceptible organisms (e.g., impetigo, infected wounds, folliculitis), Staphylococcus aureus skin infections including MRSA. Also known as: FUCIDIN OINTMENT 10%.
Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G, preventing bacterial growth.
Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G, preventing bacterial growth. Used for Bacterial skin infections caused by susceptible organisms (e.g., impetigo, infected wounds, folliculitis), Staphylococcus aureus skin infections including MRSA.
At a glance
| Generic name | Fucidin® cream |
|---|---|
| Also known as | FUCIDIN OINTMENT 10% |
| Sponsor | LEO Pharma |
| Drug class | Steroid antibiotic |
| Target | Bacterial elongation factor G (EF-G) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fusidic acid is a steroid antibiotic that binds to bacterial elongation factor G (EF-G) and inhibits translocation during protein synthesis, effectively halting bacterial protein production. This bacteriostatic mechanism makes it particularly effective against Gram-positive bacteria, especially Staphylococcus aureus including methicillin-resistant strains (MRSA). The topical cream formulation delivers high local concentrations to skin infections while minimizing systemic exposure.
Approved indications
- Bacterial skin infections caused by susceptible organisms (e.g., impetigo, infected wounds, folliculitis)
- Staphylococcus aureus skin infections including MRSA
Common side effects
- Local skin irritation
- Allergic contact dermatitis
- Burning or stinging at application site
Key clinical trials
- Fucidin® Cream in the Treatment of Impetigo (PHASE4)
- Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fucidin® cream CI brief — competitive landscape report
- Fucidin® cream updates RSS · CI watch RSS
- LEO Pharma portfolio CI
Frequently asked questions about Fucidin® cream
What is Fucidin® cream?
How does Fucidin® cream work?
What is Fucidin® cream used for?
Who makes Fucidin® cream?
Is Fucidin® cream also known as anything else?
What drug class is Fucidin® cream in?
What development phase is Fucidin® cream in?
What are the side effects of Fucidin® cream?
What does Fucidin® cream target?
Related
- Drug class: All Steroid antibiotic drugs
- Target: All drugs targeting Bacterial elongation factor G (EF-G)
- Manufacturer: LEO Pharma — full pipeline
- Therapeutic area: All drugs in Dermatology / Infectious Disease
- Indication: Drugs for Bacterial skin infections caused by susceptible organisms (e.g., impetigo, infected wounds, folliculitis)
- Indication: Drugs for Staphylococcus aureus skin infections including MRSA
- Also known as: FUCIDIN OINTMENT 10%
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing